Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

Background and Purpose Cannabinoid CB2 receptors are up‐regulated in reactive microglia in the spinal cord of TDP‐43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up‐regulation can be exploited pharmacologically, we investigated the effect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2019-05, Vol.176 (10), p.1585-1600
Hauptverfasser: Espejo‐Porras, Francisco, García‐Toscano, Laura, Rodríguez‐Cueto, Carmen, Santos‐García, Irene, Lago, Eva, Fernandez‐Ruiz, Javier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1600
container_issue 10
container_start_page 1585
container_title British journal of pharmacology
container_volume 176
creator Espejo‐Porras, Francisco
García‐Toscano, Laura
Rodríguez‐Cueto, Carmen
Santos‐García, Irene
Lago, Eva
Fernandez‐Ruiz, Javier
description Background and Purpose Cannabinoid CB2 receptors are up‐regulated in reactive microglia in the spinal cord of TDP‐43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up‐regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. Experimental Approach We treated TDP‐43 (A315T) transgenic mice with the non‐selective agonist WIN55,212‐2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU‐308, and evaluated their effects on the pathological phenotype. Key Results WIN55,212‐2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba‐1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU‐308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl‐stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU‐308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU‐308 reduced the elevated Iba‐1 immunostaining in the ventral horn of TDP‐43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. Conclusions and Implications Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. Linked Articles This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc
doi_str_mv 10.1111/bph.14216
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6487601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2296311204</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3466-db35110d51f29a4d7325ec4f57fcc8287593b83e8a392f6656fc852caa8ce8e43</originalsourceid><addsrcrecordid>eNpdks1u1DAUhSMEokNhwRtYYlMk0vondpwNUjv8FKkSXQxry3FuEleOHewMKDsegSfhoXgSPJ0KCe7GVz5Hn86VTlG8JPic5Llo5_GcVJSIR8WGVLUoOZPkcbHBGNclIVKeFM9SusM4izV_WpzQhteVkM2m-LXTcYDF-gENzmqHjPZet9YH26HtFUURDMxLiAktAXXg9IqWEdAcwxAhJRs8Cv3xSy9jcGGwJmPmEXxY1hmQ9Wj37vb3j58VQ2eXjPDda7RE7dMA3ho0WQNvkEZTyPADSk9rWGKYxyw6vUDMtGQcxJBsel486bVL8OLhPS2-fHi_216XN58_ftpe3pQzq4Qou5ZxQnDHSU8bXXU1oxxM1fO6N0ZSWfOGtZKB1KyhvRBc9EZyarSWBiRU7LR4e-TO-3aCzoDPkZ2ao510XFXQVv2reDuqIXxTopK1wCQDzh4AMXzdQ1rUZJMB57SHsE-KYiKFoALX2frqP-td2Eefz1OUNoIRQvEh0cXR9d06WP8mIVgdKqByBdR9BdTV7fX9wv4ANAynew</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2296311204</pqid></control><display><type>article</type><title>Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Espejo‐Porras, Francisco ; García‐Toscano, Laura ; Rodríguez‐Cueto, Carmen ; Santos‐García, Irene ; Lago, Eva ; Fernandez‐Ruiz, Javier</creator><creatorcontrib>Espejo‐Porras, Francisco ; García‐Toscano, Laura ; Rodríguez‐Cueto, Carmen ; Santos‐García, Irene ; Lago, Eva ; Fernandez‐Ruiz, Javier</creatorcontrib><description>Background and Purpose Cannabinoid CB2 receptors are up‐regulated in reactive microglia in the spinal cord of TDP‐43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up‐regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. Experimental Approach We treated TDP‐43 (A315T) transgenic mice with the non‐selective agonist WIN55,212‐2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU‐308, and evaluated their effects on the pathological phenotype. Key Results WIN55,212‐2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba‐1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU‐308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl‐stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU‐308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU‐308 reduced the elevated Iba‐1 immunostaining in the ventral horn of TDP‐43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. Conclusions and Implications Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. Linked Articles This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.14216</identifier><identifier>PMID: 29574689</identifier><language>eng</language><publisher>London: Blackwell Publishing Ltd</publisher><subject>Activation ; Agonists ; Amyotrophic lateral sclerosis ; Antagonists ; Astrocytes ; Cannabinoid CB2 receptors ; Genotype &amp; phenotype ; Glial fibrillary acidic protein ; Gliosis ; Horns ; Immunoreactivity ; Mice ; Microglia ; Motor neurons ; Neurons ; Phenotypes ; Preservation ; Receptor mechanisms ; Research Paper ; Rodents ; Sclerosis ; Spinal cord ; Substantia alba ; Themed Section: Research Papers ; Transgenic animals ; Transgenic mice ; Ventral horn</subject><ispartof>British journal of pharmacology, 2019-05, Vol.176 (10), p.1585-1600</ispartof><rights>2018 The British Pharmacological Society</rights><rights>2019 The British Pharmacological Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4490-0604</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487601/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487601/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808,53766,53768</link.rule.ids></links><search><creatorcontrib>Espejo‐Porras, Francisco</creatorcontrib><creatorcontrib>García‐Toscano, Laura</creatorcontrib><creatorcontrib>Rodríguez‐Cueto, Carmen</creatorcontrib><creatorcontrib>Santos‐García, Irene</creatorcontrib><creatorcontrib>Lago, Eva</creatorcontrib><creatorcontrib>Fernandez‐Ruiz, Javier</creatorcontrib><title>Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis</title><title>British journal of pharmacology</title><description>Background and Purpose Cannabinoid CB2 receptors are up‐regulated in reactive microglia in the spinal cord of TDP‐43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up‐regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. Experimental Approach We treated TDP‐43 (A315T) transgenic mice with the non‐selective agonist WIN55,212‐2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU‐308, and evaluated their effects on the pathological phenotype. Key Results WIN55,212‐2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba‐1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU‐308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl‐stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU‐308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU‐308 reduced the elevated Iba‐1 immunostaining in the ventral horn of TDP‐43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. Conclusions and Implications Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. Linked Articles This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc</description><subject>Activation</subject><subject>Agonists</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Antagonists</subject><subject>Astrocytes</subject><subject>Cannabinoid CB2 receptors</subject><subject>Genotype &amp; phenotype</subject><subject>Glial fibrillary acidic protein</subject><subject>Gliosis</subject><subject>Horns</subject><subject>Immunoreactivity</subject><subject>Mice</subject><subject>Microglia</subject><subject>Motor neurons</subject><subject>Neurons</subject><subject>Phenotypes</subject><subject>Preservation</subject><subject>Receptor mechanisms</subject><subject>Research Paper</subject><subject>Rodents</subject><subject>Sclerosis</subject><subject>Spinal cord</subject><subject>Substantia alba</subject><subject>Themed Section: Research Papers</subject><subject>Transgenic animals</subject><subject>Transgenic mice</subject><subject>Ventral horn</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdks1u1DAUhSMEokNhwRtYYlMk0vondpwNUjv8FKkSXQxry3FuEleOHewMKDsegSfhoXgSPJ0KCe7GVz5Hn86VTlG8JPic5Llo5_GcVJSIR8WGVLUoOZPkcbHBGNclIVKeFM9SusM4izV_WpzQhteVkM2m-LXTcYDF-gENzmqHjPZet9YH26HtFUURDMxLiAktAXXg9IqWEdAcwxAhJRs8Cv3xSy9jcGGwJmPmEXxY1hmQ9Wj37vb3j58VQ2eXjPDda7RE7dMA3ho0WQNvkEZTyPADSk9rWGKYxyw6vUDMtGQcxJBsel486bVL8OLhPS2-fHi_216XN58_ftpe3pQzq4Qou5ZxQnDHSU8bXXU1oxxM1fO6N0ZSWfOGtZKB1KyhvRBc9EZyarSWBiRU7LR4e-TO-3aCzoDPkZ2ao510XFXQVv2reDuqIXxTopK1wCQDzh4AMXzdQ1rUZJMB57SHsE-KYiKFoALX2frqP-td2Eefz1OUNoIRQvEh0cXR9d06WP8mIVgdKqByBdR9BdTV7fX9wv4ANAynew</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Espejo‐Porras, Francisco</creator><creator>García‐Toscano, Laura</creator><creator>Rodríguez‐Cueto, Carmen</creator><creator>Santos‐García, Irene</creator><creator>Lago, Eva</creator><creator>Fernandez‐Ruiz, Javier</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4490-0604</orcidid></search><sort><creationdate>201905</creationdate><title>Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis</title><author>Espejo‐Porras, Francisco ; García‐Toscano, Laura ; Rodríguez‐Cueto, Carmen ; Santos‐García, Irene ; Lago, Eva ; Fernandez‐Ruiz, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3466-db35110d51f29a4d7325ec4f57fcc8287593b83e8a392f6656fc852caa8ce8e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Activation</topic><topic>Agonists</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Antagonists</topic><topic>Astrocytes</topic><topic>Cannabinoid CB2 receptors</topic><topic>Genotype &amp; phenotype</topic><topic>Glial fibrillary acidic protein</topic><topic>Gliosis</topic><topic>Horns</topic><topic>Immunoreactivity</topic><topic>Mice</topic><topic>Microglia</topic><topic>Motor neurons</topic><topic>Neurons</topic><topic>Phenotypes</topic><topic>Preservation</topic><topic>Receptor mechanisms</topic><topic>Research Paper</topic><topic>Rodents</topic><topic>Sclerosis</topic><topic>Spinal cord</topic><topic>Substantia alba</topic><topic>Themed Section: Research Papers</topic><topic>Transgenic animals</topic><topic>Transgenic mice</topic><topic>Ventral horn</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Espejo‐Porras, Francisco</creatorcontrib><creatorcontrib>García‐Toscano, Laura</creatorcontrib><creatorcontrib>Rodríguez‐Cueto, Carmen</creatorcontrib><creatorcontrib>Santos‐García, Irene</creatorcontrib><creatorcontrib>Lago, Eva</creatorcontrib><creatorcontrib>Fernandez‐Ruiz, Javier</creatorcontrib><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Espejo‐Porras, Francisco</au><au>García‐Toscano, Laura</au><au>Rodríguez‐Cueto, Carmen</au><au>Santos‐García, Irene</au><au>Lago, Eva</au><au>Fernandez‐Ruiz, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis</atitle><jtitle>British journal of pharmacology</jtitle><date>2019-05</date><risdate>2019</risdate><volume>176</volume><issue>10</issue><spage>1585</spage><epage>1600</epage><pages>1585-1600</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Background and Purpose Cannabinoid CB2 receptors are up‐regulated in reactive microglia in the spinal cord of TDP‐43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up‐regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. Experimental Approach We treated TDP‐43 (A315T) transgenic mice with the non‐selective agonist WIN55,212‐2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU‐308, and evaluated their effects on the pathological phenotype. Key Results WIN55,212‐2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba‐1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU‐308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl‐stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU‐308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU‐308 reduced the elevated Iba‐1 immunostaining in the ventral horn of TDP‐43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. Conclusions and Implications Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. Linked Articles This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc</abstract><cop>London</cop><pub>Blackwell Publishing Ltd</pub><pmid>29574689</pmid><doi>10.1111/bph.14216</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-4490-0604</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2019-05, Vol.176 (10), p.1585-1600
issn 0007-1188
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6487601
source Wiley Free Content; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Activation
Agonists
Amyotrophic lateral sclerosis
Antagonists
Astrocytes
Cannabinoid CB2 receptors
Genotype & phenotype
Glial fibrillary acidic protein
Gliosis
Horns
Immunoreactivity
Mice
Microglia
Motor neurons
Neurons
Phenotypes
Preservation
Receptor mechanisms
Research Paper
Rodents
Sclerosis
Spinal cord
Substantia alba
Themed Section: Research Papers
Transgenic animals
Transgenic mice
Ventral horn
title Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A36%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20glial%20cannabinoid%20CB2%20receptors%20to%20delay%20the%20progression%20of%20the%20pathological%20phenotype%20in%20TDP%E2%80%9043%20(A315T)%20transgenic%20mice,%20a%20model%20of%20amyotrophic%20lateral%20sclerosis&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Espejo%E2%80%90Porras,%20Francisco&rft.date=2019-05&rft.volume=176&rft.issue=10&rft.spage=1585&rft.epage=1600&rft.pages=1585-1600&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.14216&rft_dat=%3Cproquest_pubme%3E2296311204%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2296311204&rft_id=info:pmid/29574689&rfr_iscdi=true